The system sends a message from the pill's sensor to a wearable patch, which then transmits the information to a mobile application, so that patients can track the ingestion of the medication on their smartphone. Patients can allow their caregivers and physician to access the information through a web-based portal.
The prescribing notes also stress that Abilify MyCite should not be used to track drug ingestion in "real-time" or during an emergency, because detection may be delayed or may not occur.
"The FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers".
In Australia, Abilify is used to treat symptoms of schizophrenia and mania in bipolar disorder.
The U.S. Food and Drug Administration (FDA) has reportedly approved a pill that is endowed with a unique digital tracking device.
The permit has been granted to Abilify MyCite's Japanese maker Otsuka Pharmaceutical, while the sensor technology and patch are made by Californian medical technology business Proteus Digital Health.
While patients could choose not to take the pill, its approval could raise questions about privacy and whether some patients might feel pushed into taking the digital pill.
In a statement, Proteus Digital Health CEO Andrew Thompson said he believed the time was right to make this type of technology available to people with serious mental illnesses.
"Consumers already manage important tasks like banking, shopping, and communicating with friends and family by using their smart phones, as they go about their daily lives".